Newsfeeds - Spark Newswire

2 minute read

Prothena Reports FDA Clearance Of Its Investigational New Drug Application For Subcutaneous Anti-Amyloid Beta Antibody Under Investigation For Treatment Of Alzheimer’s

Today, 9:12 PM

Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer’s disease DUBLIN, Ireland, March 28, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a

PRTA

1 minute read

Prothena Highlinghts New Preclinical Data For Alzheimer’s, Parkinson’s Vaccine Programs

By Vandana Singh

Today, 9:12 PM

Prothena Corporation plc (NASDAQ: PRTA)

PRTA

1 minute read

Prothena Corp Q4 EPS $(0.71) Misses $(0.58) Estimate

By Benzinga Newsdesk

Today, 9:12 PM

Prothena Corp (NASDAQ:PRTA) reported quarterly losses of $(0.71) per share which missed the analyst consensus estimate of $(0.58) by 22.41 percent. This is a 7.79 percent increase over losses of $(0.77) per share from

PRTA

10 minute read

Earnings Scheduled For February 17, 2022

By Benzinga Insights

Today, 9:12 PM

Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million.

AAWW

3 minute read

The Week Ahead In Biotech (Feb. 13-19): Agios FDA Meeting, Avenue Adcom, Earnings And More

By Shanthi Rexaline

Today, 9:12 PM

Biotech stocks moved back and forth amid some volatility before finishing the week ending Feb. 11 modestly lower, reversing the gains from the previous week. Earnings news flow continued to dominate proceedings, and the week also witnessed presentations at conferences and a couple of initial public offerings.

ADPT

4 minute read

The Daily Biotech Pulse: Adagio’s Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact

By Shanthi Rexaline

Today, 9:12 PM

Here's a roundup of top developments in the biotech space over the last 24 hours:

ADAG

2 minute read

4 Stocks Insiders Are Buying

By Lisa Levin

Today, 9:12 PM

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock. Insider purchases should not be taken as the only indicator for making an investment or trading decision. At best, it can lend conviction to a buying decision.

ANGO

2 minute read

Movers

12 Health Care Stocks Moving In Wednesday’s After-Market Session

By Benzinga Insights

Today, 9:12 PM

Gainers Biomerica (NASDAQ:BMRA) stock increased by 10.2% to $4.95 during Wednesday's after-market session. The market value of their outstanding shares is at $61.9 million. As per the news, the Q2 earnings report came out today.

ABEO

2 minute read

Mid-Morning Market Update: Markets Open Higher; US Inflation Rate Rises To 7% In December

By Lisa Levin

Today, 9:12 PM

Following the market opening Wednesday, the Dow traded up 0.56% to 36,453.49 while the NASDAQ rose 0.79% to 15,273.08. The S&P also rose, gaining, 0.60% to 4,741.45.

AACG

1 minute read

JMP Securities Initiates Coverage On Prothena Corp with Market Outperform Rating, Announces Price Target of $77

By Benzinga Newsdesk

Today, 9:12 PM

JMP Securities analyst Gobind Singh initiates coverage on Prothena Corp (NASDAQ:PRTA) with a Market Outperform rating and announces Price Target of $77.

PRTA